Wj. Mroczek et M. Stimpel, A DOUBLE-BLIND EVALUATION OF MOEXIPRIL VERSUS HYDROCHLOROTHIAZIDE IN HYPERTENSION, Advances in therapy, 13(2), 1996, pp. 79-87
Citations number
6
Categorie Soggetti
Medicine, Research & Experimental","Pharmacology & Pharmacy
Moexipril is the prodrug of a new long-acting nonpeptide, nonsulfhydry
l angiotensin-converting enzyme (ACE) inhibitor. After once-daily oral
administration, moexipril in doses of 7.5 mg, 15 mg, or 30 mg demonst
rates potent and specific competitive inhibition of ACE. Maximum reduc
tions in blood pressure are seen within 3 to 6 hours of administration
, and the antihypertensive effect persists for up to 24 hours. Two hun
dred thirty-eight patients with mild to moderate hypertension entered
a single-blind placebo period. Of these, 200 patients subsequently ent
ered a double-blind parallel study comparing moexipril 7.5 mg and 15 m
g, hydrochlorothiazide (HCTZ) 25 mg, and placebo once a day for 12 wee
ks. At the last predose measurement during the double-blind period, re
ductions in mean sitting diastolic blood pressure were 7.9 and 8.3 mm
Hg with moexipril 7.5 mg and 15 mg, 3.1 mm Hg with placebo, and 8.8 mm
Hg with HCTZ. Reductions were statistically significant at each 2-wee
k measurement for all groups compared with placebo, except at week 10.
Adverse effects were comparable in all drug groups and in the placebo
group. in this double-blind study, the antihypertensive effect of bot
h moexipril doses was comparable to that of HCTZ 25 mg daily. Moexipri
l 7.5 mg and 15 mg given once daily to patients with mild to moderate
hypertension produced prompt, clinically important reductions in eleva
ted blood pressure.